Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients

European Journal of Neurology

Volumn 20, Issue 7, 2013, Pages 1043-1052

  Leinonen, V ^a   Rinne, J O ^b   Virtanen, K A ^b   Eskola, O ^b   Rummukainen, J ^a   Huttunen, J ^a   Von und zu Fraunberg, M ^a   Nerg, O ^a,c   Koivisto, A M ^a,c   Rinne, J ^a   Jaaskelainen J E ^a   Buckley, C ^d   Smith, A ^d   Jones, P A ^d   Sherwin, P ^e   Farrar, G ^d   Mclain, R ^f   Kailajarvi M ^g   Heurling, K ^h   Grachev, I D ^e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d GE HEALTHCARE   (United Kingdom)

^e GE HEALTHCARE   (United States)

^f PFP Statistical Consulting LLC   (United States)

^g GE Healthcare Finland Oy   (Finland)

^h BIACORE AB   (Sweden)

Author keywords

Alzheimer's disease; Brain amyloid ; Brain biopsy; Flutemetamol; Normal pressure hydrocephalus; Pittsburgh compound B; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLUTEMETAMOL F 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G8; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANASTOMOSIS; ARTICLE; BRAIN BIOPSY; BRAIN CORTEX; BRAIN TISSUE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DRUG INDUCED HEADACHE; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRACRANIAL PRESSURE MONITORING; MALE; MINI MENTAL STATE EXAMINATION; NORMOTENSIVE HYDROCEPHALUS; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TEMPORAL CORTEX; THROAT IRRITATION;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BENZOTHIAZOLES; BIOPSY; CEREBRAL CORTEX; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; PLAQUE, AMYLOID; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 84879011614     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12102     Document Type: Article

References (31)

1. Cotran RS, Kumar V, Robbins SL. Amyloidosis. In: Kumar V, Abbas AK, Aster J, Fausto N, eds. Robbins Pathologic Basis of Disease. Philadelphia, PA: WB Saunders, 1989: 210-220.
2. Harrison RS, Sharpe PC, Singh Y, Fairlie DP. Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 2007; 159: 1-77.
3. Cotran RS, Kumar V, Robbins SL. Alzheimer's disease. In: Kumar V, Abbas AK, Aster J, Fausto N, eds. Robbins Pathologic Basis of Disease. Philadelphia, PA: WB Saunders, 1989: 1427-1429.
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
5. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
6. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-1309.
7. Leinonen V, Koivisto AM, Savolainen S, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010; 68: 446-453.
8. Vallet PG, Guntern R, Hof PR, et al. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 1992; 83: 170-178.
9. Cooper JH. An evaluation of current methods for the diagnostic histochemistry of amyloid. J Clin Pathol 1969; 22: 410-413.
10. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association roundtable Workgroup. Alzheimer's Dement 2011; 7: 367-385.
11. Wu C, Pike VW, Wang Y. Amyloid imaging: from benchtop to bedside. Curr Top Dev Biol 2005; 70: 171-213.
12. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645.
13. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer's disease. J Nucl Med 2009; 50: 1251-1259.
14. Edison P, Hinz R, Brooks DJ. Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimer's Res Ther 2011; 3: 25.
15. Golomb J, Wisoff J, Miller DC, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000; 68: 778-781.
16. Hamilton R, Patel S, Lee EB, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 2010; 68: 535-540.
17. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011; 7: 263-269.
18. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011; 7: 270-279.
19. Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Meth 2008; 172: 277-282.
20. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680.
21. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.
22. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage 2008; 42: 559-567.
23. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-329.
24. Leinonen V, Koivisto AM, Savolainen S, et al. Post-mortem findings in 10 patients with presumed normal pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol 2012; 38: 72-86.
25. Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012; 79: 1570-1577.
26. (18)F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imag Biol 2012; [Epub ahead of print].
27. 18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124: 833-845.
28. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398-1403.
29. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
30. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090.
31. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.